

2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Effect of chitosan-coated and pure PLLA scaffolds composition and structure on the chondrogenesis of mesenchymal stem cells**

Joana Magalhães, PhD,<sup>1,2</sup> Myriam Lebourg, PhD,<sup>1,3</sup>, Harmony Deplaine, PhD,<sup>3</sup>  
José Luis Gómez Ribelles, PhD,<sup>1,3</sup> Francisco J. Blanco, MD, PhD<sup>2</sup>

<sup>1</sup> Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Spain.

<sup>2</sup> Grupo de Bioingeniería Tisular y Terapia Celular (CBTTC-CHUAC). Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complejo Hospitalario Universitario de A Coruña (CHUAC). Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, Spain.

<sup>3</sup> Centro de Biomateriales e Ingeniería Tisular, Universidad Politécnica de Valencia. Camino de Vera s/n 46071, Edificio 8E, Planta 1. Valencia, Spain.

Correspondence should be sent to: Francisco J. Blanco, Joana Magalhães. Grupo de Bioingeniería Tisular y Terapia Celular (CBTTC-CHUAC). Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complejo Hospitalario Universitario de A Coruña (CHUAC). Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, Spain. Tel: +34981176399. Fax: +34981176398 Email: [fblagar@sergas.es](mailto:fblagar@sergas.es), [joana.cristina.silva.magalhaes@sergas.es](mailto:joana.cristina.silva.magalhaes@sergas.es)

1  
2  
3 **Abstract**  
4

5 Due to the attractive properties of poly(L-lactic acid) (PLLA) and chitosan (CHT)  
6 for tissue engineering applications, this study is aimed at analyzing the  
7  
8  
9  
10 chondrogenic potential of human bone marrow derived-mesenchymal stem cells  
11 (BM-MSCs) in PLLA, pure or combined with CHT, using different coating  
12 methodologies. Whilst PLLA scaffolds coated in one-step (PLLA-CHT1) yielded  
13  
14 CHT smooth pellicles within PLLA macropores, a two-step strategy resulted in a  
15  
16 CHT fiber-like coating within PLLA micropores. Both strategies led to the  
17  
18  
19 incorporation of similar content of CHT and a 2-fold increase in the scaffolds  
20  
21 water uptake capacity, providing elastic moduli values comparable to the ones  
22  
23 found for human articular cartilage. After confirming BM-MSCs metabolic  
24  
25 activity in PLLA-CHT scaffolds, the chondrogenic potential was tested at 30 and  
26  
27  
28  
29  
30 60 days, in a chondrogenic differentiation medium. PLLA scaffolds improved the  
31  
32 chondrogenic differentiation of BM-MSCs, regarding cell pellet conventional  
33  
34 culture. On the long term, pure PLLA induced the production of a transient  
35  
36 cartilage-like phenotype that couldn't be reverted by the presence of chitosan.  
37  
38 Moreover, the process of CHT coating led to differences on the MSCs  
39  
40  
41 chondrogenic differentiation process, forming either rather heterogeneous  
42  
43 tissues, with confined areas of faster maturation or slower cell infiltration (PLLA-  
44  
45 CHT1), or a more homogeneously distributed extracellular matrix (PLLA-CHT2),  
46  
47  
48 which could be useful for developing a zonal distribution typically presented in  
49  
50 healthy articular cartilage.  
51

52  
53 **Keywords:** mesenchymal stem cells, poly(L-lactic acid), chitosan, cartilage  
54  
55  
56 tissue engineering, osteoarthritis

## 1. INTRODUCTION

Osteoarthritis (OA) is a degenerative disease characterized by the degradation of articular cartilage. (1) One of the primary risk factors for OA is joint injury, and cartilage defects, such as focal chondral or osteochondral lesions, tend to progress in people with symptomatic OA. (2) Human bone marrow mesenchymal stem cells (BM-MSCs) have been presented as candidate cells for cartilage repair due to their ability to undergo chondrogenic differentiation after extensive expansion *in vitro* and stimulation with various biomaterials. (3, 4)

The nature and physicochemical properties of three-dimensional scaffolds offer opportunities for lineage-specific biochemical and biophysical cues to enhance selective differentiation of MSCs and subsequent production of matrix. (5-7) Hybrid scaffolds are therefore attractive to create biomimetic environments promoting the formation of complex tissues such as those found in the osteochondral milieu. To date, a range of biomaterial scaffolds based on natural and synthetic origin polymers have been widely investigated for tissue repair and regeneration. (8-10)

Poly(L-lactic acid) (PLLA) is a commonly used synthetic polymer that can be fabricated into complex shapes via a wide range of technologies presenting tunable mechanical and structural properties. (11, 12) This FDA-regulated material is biocompatible, and degrades gradually to natural metabolites, having been used clinically in both bone and cartilage repair strategies. (13, 14)

However, due to PLLA inherent hydrophobic nature, different studies have pointed out the reduction of expression of osteoblastic phenotypic markers as well as a negative influence on cell attachment and proliferation, due to the

1  
2  
3 denaturation of adhesive ligands of cells. (13) In order to overcome these  
4 drawbacks, several groups have focused on the grafting of hydrophilic and/or  
5 natural origin materials to PLLA, improving tissue repair and regeneration  
6  
7  
8  
9  
10 processes. (15-19) Chitosan (CHT), [poly- $\beta$ (1-4)-2-amino-2-deoxy-D-glucose],  
11  
12 is one of the most abundant natural amino polysaccharides, with structural  
13 characteristics similar to glycosaminoglycans (GAGs) present in the  
14 extracellular matrix of cartilage. It is known to be non-toxic, biocompatible and  
15  
16 biodegradable. (20, 21) Moreover, the presence of  $-\text{NH}_2$  groups, makes it  
17  
18 soluble in acid solutions. (22) The applications of cationic chitosan include drug  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

In this work, PLLA scaffolds were modified using CHT following two different coating strategies. We investigated the influence of their morphology and chemical composition on the chondrogenic differentiation of BM-MSCs, providing more insight for their potential as scaffolds for osteochondral tissue engineering applications.

## 2. Materials and methods

### 2.1. Materials

#### 2.1.1. PLLA scaffold fabrication

PLLA scaffolds were prepared by a mixed technique of phase separation and porogen as described previously. (25, 26) Shortly, PLLA (Cargill Dow) solution in dioxane (15% w/v) was mixed to an equal quantity of acrylic microspheres (Lucite International) in a Teflon crystallizer and quenched in liquid nitrogen. Dioxane extraction was carried out by ethanol washes, at  $-20\text{ }^{\circ}\text{C}$ , for three days followed by porogen extraction using ethanol, at  $40\text{ }^{\circ}\text{C}$ , until the acrylic filler was

1  
2  
3 no longer detected in the washing solvent. Scaffolds were air-dried during 24h  
4  
5 and afterwards under vacuum until constant weight.

### 6 7 **2.1.2. PLLA-CHT scaffold fabrication**

8  
9  
10 PLLA scaffolds were filled with a chitosan solution (0.5% w/v, Novamatrix) in  
11  
12 acetic acid (1%), under vacuum. For PLLA-CHT1, excess CHT was removed  
13  
14 and scaffolds were quenched in liquid nitrogen; for PLLA-CHT2, CHT coating  
15  
16 was dried at 37 °C for 24h; this procedure was repeated three times. Then  
17  
18 chitosan filling or coating was gelled at -20 °C, in a pre-cooled sodium  
19  
20 hydroxide (0.1M)-ethanol solution (1:1), during 3 days. (27, 28) Subsequently,  
21  
22 samples were extensively washed in distilled water, until pH remained neutral,  
23  
24 and either: freeze-dried (PLLA-CHT1) under 0.001 mbar for 48h (Lyoquest,  
25  
26 Telstar), or air-dried for 24h and thereafter under vacuum (PLLA-CHT2) until  
27  
28  
29 constant weight.

## 30 31 **2.2. Characterization**

### 32 33 **2.2.1. Morphology**

34  
35 Prior observation with scanning electron microscopy (SEM), samples were  
36  
37 cryofractured in liquid nitrogen and mounted on copper stubs with graphite  
38  
39 adhesive tape. Samples were gold sputtered and observed in a JEOL JSM6300  
40  
41 microscope, at an acceleration tension of 15kV.  
42  
43

### 44 45 **2.2.2. Porosity**

46  
47 Porosity was determined by a gravimetric method, as the quotient of the volume  
48  
49 of pores and the total volume of the scaffold. Briefly, dry samples were weighed,  
50  
51 filled with ethanol under vacuum, and re-weighed. The volume of pores,  $V_{pore}$ ,  
52  
53 was obtained from the weight difference between the dry ( $m_{dry}$ ) and wet ( $m_{wet}$ )  
54  
55 sample, according to equation (1) assuming that the amount of ethanol  
56  
57  
58  
59  
60

absorbed by the blends is negligible, during the time of the experiment. Thus, the volume of the pores equals the volume occupied by the absorbed ethanol.

$$V_{pore} = \frac{m_{wet} - m_{dry}}{d_{ethanol}} \quad (1)$$

where  $d_{ethanol}$  is the density of ethanol. The volume occupied by the polymer was calculated from the dry weight of the scaffold assuming a density of PLLA of 1.29 g/cm<sup>3</sup> for crystalline phase and 1.19 g/cm<sup>3</sup> for amorphous phase. (29)

Five measurements were carried out for each scaffold.

### 2.2.3. Chitosan content in PLLA-CHT samples

Thermogravimetric analysis (SDTQ600, TA Instruments) was used to determine the quantity of CHT effectively coated. The samples (triplicate) were subjected to a temperature ramp from room temperature until 800 °C, at 20 °C/min under nitrogen flow (50 ml/min). The quantity of CHT in the samples was determined based on the fact that CHT leaves a dry residue of 30% at 700 °C whilst PLLA does not leave any.

### 2.2.4. Equilibrium swelling ratio

For water content analysis, samples (n = 5) were immersed in distilled water, until equilibrium was reached (48h). Samples were weighed in the dry ( $W_d$ ) and wet ( $W_s$ ) states and the equilibrium swelling ratio was calculated according to equation (2):

$$\text{Equilibrium Swelling Ratio} = \frac{W_s}{W_d} \quad (2)$$

### 2.2.5. Unconfined compression tests

Samples were submitted to a compression ramp in a Microtest standard compression machine with a 15N load cell. For wet samples, scaffolds were hydrated with distilled water, at room temperature, for 24h. Using the

1  
2  
3 methodology from ASTM D1621-04a norm “Compression of rigid cellular  
4 plastics”, for compression testing of porous samples, modulus (E) was  
5 calculated from a linear regression of the elastic zone and the yield strength  
6  
7  
8  
9  
10 (Ys), that represents the value of tension by which the pores start to collapse,  
11 was determined as the stress value at the end of the elastic zone and beginning  
12 of the plateau zone. Five measurements were performed.  
13  
14

### 15 16 **2.3. Cells**

17 Human mesenchymal stem cells were isolated from bone marrow (BM) samples  
18  
19 obtained from seven patients undergoing total hip replacement due to  
20 osteoarthritis. All patients signed an informed consent agreement form,  
21 approved by the Ethics Committee of Clinical Research of Galicia (CEIC). BM-  
22 MSCs were cultured in expansion medium (EM) composed by Dulbecco’s  
23  
24 modified Eagles medium (DMEM) supplemented with 20% fetal bovine serum  
25 (FBS) and penicillin/streptomycin (10,000 IU/mL) (all from Sigma-Aldrich) until  
26 90% confluent. Pre-plating technique was performed in order to avoid any  
27 remaining fibroblasts. (3) Phenotypic characterization and multipotential  
28 characterization (adipogenic and osteogenic differentiation) were performed  
29  
30 using standardized protocols. (30)  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

### 41 42 **2.4. Cellular studies**

#### 43 44 **2.4.1. Viability Assay**

45 PLLA, PLLA-CHT1 and -CHT2 scaffolds (6mm Ø x1mm) were sterilized prior to  
46 cell seeding. Briefly,  $3 \times 10^5$  BM-MSCs (P3), suspended in 50  $\mu$ l EM were  
47 seeded on the scaffolds (each in triplicate) placed individually on a 24-well cell  
48 culture plate and allowed to adhere for 2h before the addition of 1 ml of EM.  
49 Cellular metabolic activity was followed during 48h, 14 and 30 days, using the  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 alamar blue manufacturer's specifications (Invitrogen). Cells-only cultured on  
4  
5 tissue-cultured polystyrene wells (TCPS) were used as reference.  
6  
7

#### 8 9 **2.4.2. Chondrogenic differentiation**

10  
11 BM-MSCs were seeded in pure and CHT-coated PLLA, as previously  
12 described, and incubated in a well-defined chondrogenic differentiation medium  
13 (CM) composed by DMEM supplemented with knock-out serum (15%), ascorbic  
14 acid (10  $\mu$ l/ml), transferrin (6  $\mu$ l/ml), dexamethasone (10  $\mu$ M), retinoic acid (10<sup>-7</sup>  
15 M) and transforming growth factor beta 3 (TGF- $\beta$ 3, 10 ng/ml), at 37 °C, under  
16  
17  
18  
19  
20  
21 5% CO<sub>2</sub>, for 30 and 60 days. MSC pellet culture system was modified from  
22  
23 Zhang *et al.*, and used as control. (31) Briefly, 2.5 x 10<sup>5</sup> cells, suspended in 500  
24  
25  $\mu$ l CM, were centrifuged at 600 x g for 10 min, in 15-ml polypropylene conical  
26  
27 tubes. Pelleted cells were incubated in the same conditions as cell-constructs.  
28  
29

#### 30 31 **2.4.3. Histology and immunohistochemistry**

32  
33 Pellets from BM-MSCs, following differentiation into chondrocyte-like cells, were  
34 frozen in OCT embedding matrix (Sakura). Bisected cell-constructs were fixed  
35 in 4% (w/v) paraformaldehyde (Sigma) and embedded in paraffin. Histological  
36  
37 staining was performed with hematoxylin and eosin (HE), safranin-O (SaO),  
38  
39 toluidine blue (TB), as well as alizarin red and Von Kossa staining, in order to  
40  
41 detect matrix mineralization. Immunohistochemical labeling was performed for  
42  
43 collagen type-II (col-II), aggrecan and lubricin; collagen type- I (col-I) and type-X  
44  
45 (col-X). For this, cryosections of 4  $\mu$ m were deparaffinised, hydrated in serial  
46  
47  
48  
49  
50 graded alcohol, pre-treated with chondroitinase-ABC (Sigma) and  
51  
52 immunostained with monoclonal antibodies. Secondary antibodies were  
53  
54 detected using a polymer-labelled HRP complex (Kit Envision Detection  
55  
56 Systems Peroxidase/DAB, DAKO) with diaminobenzidine substrate.  
57  
58  
59  
60



1  
2  
3 Quantification of positive expression for collagens was performed using  
4 analiSIS software (version D) (Olympus). The values were expressed as the  
5 percentage of positive staining normalized against the total area of matrix  
6  
7  
8  
9 produced.

#### 10 11 **2.4.4. Gene expression analysis**

12 Total RNA was isolated from both cell-pellets and cell-constructs using a  
13 RNeasy minikit (Quiagen). Briefly, samples were transferred to RNase-free  
14 microcentrifuge tubes containing cell lysis buffer from the RNeasy minikit and  
15  
16 pulverized in a micro-dismembrator (Retsch MM200). Complete  
17 homogenization was performed using a QIAshredder column. The  
18 homogenates were then transferred to spincolumns from the RNeasy minikit  
19 according to the manufacturer's protocol. The RNA samples were treated with  
20  
21 DNase and converted into cDNA using the SuperScript VILO cDNA synthesis  
22 kit (Invitrogen). Gene expression was measured by real-time reverse  
23 transcription polymerase chain reaction (qRT-PCR), conducted in a  
24 LightCycler® 480 Instrument (Roche) using the LightCycler® 480 Probes  
25 Master protocol. Amplification of mRNA was performed using custom primers  
26  
27 shown in Table 1. Beta-2-Microglobulin (B2M) and Ribosomal Protein L13a  
28 (RPL13a) were used as housekeeping genes (HKG). Relative levels of  
29 expression were calculated by the  $2^{-\Delta\Delta Ct}$  method. (32) Data were normalized  
30 against the values obtained for the cell-pellet control for each gene, which was  
31  
32 assigned the value of 1, and were measured as relative expression levels.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

#### 50 51 **2.5. Statistical analysis**

52  
53  
54  
55  
56  
57  
58  
59  
60

All data presented are expressed as mean  $\pm$  standard deviation (SD). Statistical comparisons were carried out using one-way analysis of variance (ANOVA). Values of  $p < 0.05$  were considered statistically significant.

### 3. Results

#### 3.1. Morphology and porosity

Freeze-gelation, extraction and drying processes were critical in influencing scaffolds architecture, depicted in Figure 1. PLLA scaffolds present a double porosity (macro and micro), spherical interconnected pores ( $153 \pm 51 \mu\text{m}$ ) and a porosity of  $88 \pm 2\%$  (Figure 1A). The steps involved in CHT coating, did not seem to affect the microporous structure of PLLA but mainly how CHT coating remained distributed within the scaffold. On one hand in PLLA-CHT1, the hydrogel phase of CHT filled the macroporous space of the PLLA scaffold, as rather continuous smooth pellicles (arrow on Figure 1B). On the other hand in PLLA-CHT2 (Figure 1C), CHT tended to generate a fibrous-like coating over PLLA micropores. Nonetheless, PLLA-CHT2 overall porous structure was found very similar to pure PLLA.

#### 3.2. CHT content and equilibrium swelling ratio

The decomposition profiles for PLLA, PLLA-CHT1 and -CHT2 are represented in Figure 2A. On a first region of thermal degradation, up to  $200^\circ\text{C}$ , the weight loss differences among the pure and coated PLLA are linked to the presence of moisture due to the introduction of the hydrophilic component - CHT. For both CHT-coated PLLA, the onset of PLLA thermal degradation shifted to lower temperatures, which is correlated to a slight decrease observed for the molecular weight (S01). After the main degradation, chitosan was obtained as the final product, with  $5 \pm 0.8\%$  (PLLA-CHT1) and  $6 \pm 1\%$  (PLLA-CHT2) contents.

1  
2  
3 Incorporation of CHT into hydrophobic PLLA scaffolds provoked an increase of  
4 the swelling ratio which was found similar,  $8.3\pm 0.5$  (PLLA-CHT1) and  $8.3\pm 0.7$   
5 (PLLA-CHT2), despite of the coating methodology followed (Figure 2B).  
6  
7  
8  
9

### 10 **3.3. Mechanical properties**

11 Strain stress curves are represented in **Error! Reference source not found.** 3 (A, B).  
12 These can be divided in three zones as usually observed in porous scaffolds;  
13 (33) The first linear zone corresponds to the elastic deformation of the whole  
14 structure (strain 0-0.15); a second linear zone, with reduced slope corresponds  
15 to the progressive bending of the struts between the pores, according to the  
16 material porosity (strain 0.15-0.5), which leads to a structure densification with  
17 increasing slope (strain 0.5-0.8). Whereas only the first zone is observed in pure  
18 PLLA, in both CHT-coated PLLA scaffolds one can observe the three  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
aforementioned zones. The strain-stress profiles show a similar trend in both  
dry (Figure 3A) and wet states (Figure 3B), even though the slopes are  
generally reduced in the latest due to the loss of rigidity in the presence of  
water. As observed in Figure 3 (C, D), PLLA shows major rigidity and strength,  
in both states, with minor variation related to its hydrophobicity. CHT-coating  
induced a softening of pure PLLA ( $2.28\pm 0.45$  MPa), expressed by a decrease of  
the modulus value;  $0.82\pm 0.1$  MPa and  $0.73\pm 0.36$  MPa for PLLA-CHT1 and -  
CHT2, respectively, in the dry state (Figure 3C). In concurrence, the yield  
strength (Figure 3D) follows the same trend, revealing decreased values of  
 $0.17\pm 0.08$  MPa (PLLA-CHT1) and  $0.09\pm 0.03$  MPa (PLLA-CHT2), regarding  
pure PLLA.

### 54 **3.4. Cell viability**

1  
2  
3 During the follow-up period BM-MSCs cultured in the scaffolds remained  
4 metabolically active (Figure 4), showing a similar trend in their behavior, slightly  
5 decreasing their activity on day 14 and reaching a peak on cell proliferation,  
6  
7  
8  
9  
10 after 30 days. No significant differences were found amongst the 3 scaffolds  
11  
12 neither regarding TCPS ( $p > 0.05$ ).

### 13 14 **3.5. BM-MSCs chondrogenic differentiation**

15  
16 After chondrogenic differentiation induction (30 days), histological examination  
17 of the engineered tissues in PLLA constructs revealed specific cell morphology  
18  
19 along a vertical axis: a superficial region with flattened and elongated aligned  
20  
21 cells; a middle and bulk region with the presence of few fibroblastic cells and a  
22  
23 majority of rounded cells, oriented perpendicular to the surface, embedded in  
24  
25 significant amounts of extracellular matrix (Figure 5, brackets in TB). These  
26  
27  
28  
29  
30 areas have shown to be immunopositive for zone-specific marker lubricin and  
31  
32 for cartilage-specific markers, col-II and aggrecan, suggesting active  
33  
34 proteoglycan synthesis and turnover and the formation of a hyaline-like tissue.  
35  
36 In addition, PLLA revealed the highest percentage of col II-positive cells, and  
37  
38 col-II/-I ratio, regarding CHT-coated scaffolds (Table 2).

39  
40  
41 PLLA-CHT1 synthesized a hyaline-like ECM, where most of the cells exhibited  
42  
43 chondrocytic rounded morphology, supported by strong toluidine blue and  
44  
45 safranin-O stainings as well as the immunolocalized col-II and aggrecan (Figure  
46  
47  
48 5). Nonetheless, these findings were confined to small regions of the construct,  
49  
50  
51 having presented the lowest area covered by extracellular matrix (data not  
52  
53 shown). These regions, expressed col-I and -X and were positively stained for  
54  
55 alizarin red (Figure 5). Interestingly, at this time point, PLLA-CHT1 favored a  
56  
57  
58  
59  
60

1  
2  
3 similar deposition of col-II in comparison to PLLA, albeit with an overall lower  
4  
5 percentage of col-X positive cells (Table 2).  
6

7  
8 Cells in PLLA-CHT2 were morphologically comparable to the ones in PLLA and  
9  
10 seemed to follow a similar distribution, but at the same time presented the  
11  
12 lowest ratios for col-II/-I and -X (Table 2) and stained positive for alizarin red  
13  
14 (Figure 5).  
15

16  
17 By day 60, cells at both PLLA and PLLA-CHT2 revealed various characteristics  
18  
19 of a matured cartilaginous tissue, as evidenced by the presence of condensed  
20  
21 cells in lacunae and nesting cells (Figure 5, arrows in TB). On the other hand, in  
22  
23 PLLA-CHT1, where an early maturation had occurred by day 30, very few cells  
24  
25 with less abundant matrix could be appreciated, associated with a weaker  
26  
27 retention for GAGs (Figures 5, TB and SaO). Furthermore, there was a dramatic  
28  
29 decrease of the ratios of col-II/-I or -X, which could be an indicative of matrix  
30  
31 hypertrophy (Table 2). For the 3 scaffolds, alizarin red was found positive whilst  
32  
33 Von Kossa staining remained negative throughout the entire experiment (Figure  
34  
35  
36  
37 5).  
38

### 39 **3.6. Gene Expression Analysis**

40  
41 qRT-PCR revealed differences in the relative gene expression level of the  
42  
43 transcription factors Sox9, Runx1, aggrecan, col-II and hypertrophy-related  
44  
45 markers, Runx2, col-I and -X, matrix-degrading enzyme metalloprotease 13  
46  
47 (MMP13) and osteopontin (OPN), after 30 days of chondrogenic induction  
48  
49 (Figure 6). Sox9 expression in PLLA showed an increase of 2.0-fold over pellet  
50  
51 culture, meanwhile in PLLA-CHT1 and -CHT2 it was slightly downregulated. A  
52  
53 similar trend was observed for aggrecan although with a marked  
54  
55 downregulation in both CHT-coated PLLA. At the same time we found  
56  
57  
58  
59  
60

1  
2  
3 upregulated the expression of col-II in PLLA (4.0-fold) whilst CHT-coated  
4 scaffolds revealed a very low expression of this marker, even regarding the  
5 conventional pellet culture. Both col-I and -X expressions had an increase of  
6  
7 2.0-fold and 5.0-fold, respectively, regarding pellet culture; the expression was  
8  
9 downregulated in the CHT-coated scaffolds. We couldn't find any significant  
10  
11 difference amongst the scaffolds in the expression of Runx1 nor Runx2,  
12  
13 although it was in all instances higher than in pellet culture. The expression of  
14  
15 MMP13 was found higher in the 3 systems in comparison with pellet culture,  
16  
17  
18 with PLLA the highest upregulation (5.0-fold). Osteopontin was found  
19  
20 downregulated.

21  
22 After long-term culture (60 days), Sox9 was downregulated in all conditions,  
23  
24 although only significant for pure PLLA. Col-II revealed a similar trend, being  
25  
26 almost inexistent for PLLA-CHT1. On the other hand, aggrecan expression  
27  
28 remained unchanged. Col-I and -X expression was slightly upregulated in the 3  
29  
30 scaffolds. Runx1 decreased in all systems, in opposite to Runx2 and MMP13  
31  
32 that were upregulated in CHT-coated scaffolds. In PLLA, Runx2 and MMP13  
33  
34 decreased whilst OPN was significantly upregulated.  
35  
36  
37  
38

#### 39 40 41 **4. Discussion**

42  
43 Biodegradable polymers as PLLA have a more than 30 years history of safe use  
44  
45 in the medical field. Nonetheless PLLA has some inherent disadvantages for its  
46  
47 application in tissue-engineered cartilage; its rigidity, considered appropriate for  
48  
49 bone could limit their application for softer tissues and the lack of cell  
50  
51 recognition sites does not favor cellular interaction. (34, 35) These could be  
52  
53 overcome by the addition of natural hydrophilic components such as chitosan.  
54  
55  
56 (36)  
57  
58  
59  
60

1  
2  
3 In our study, the key to fabricate PLLA-CHT scaffolds was to choose proper  
4 solvents and controlled extraction-gelation parameters. The prepared systems  
5 presented different morphology that could at least be partially related to the  
6  
7 methodologies used for their fabrication. (36, 37) Hence in PLLA-CHT1 (Figure  
8 1B), a hydrogel-like coating, confined within a rather heterogeneous  
9 macroporous structure, resulted from freeze-gelation and freeze-drying  
10 processes, whilst in PLLA-CHT2 (Figure 1C), a fiber-like coating, resulted from  
11 drying the CHT solution on the surface of PLLA and neutralizing by air-drying.  
12  
13 The incorporation of similar contents of CHT (5-6%) (Figure 2A) led to a  
14 softening of PLLA, comprising elastic moduli values (Figure 3D) in the range of  
15 those found in the literature for human articular cartilage (0.1 to 2.5 MPa). (38)  
16 Due to its abundant number of hydrophilic groups, CHT-coating also improved  
17 PLLA hydrophilicity, observed by an increase of the water uptake ratios (Figure  
18 2B). (9) Further, the solvents used did not dramatically alter the molecular  
19 weight and polydispersity of CHT-coated scaffolds (SO1). Thus the presence of  
20 short oligomeric chains was excluded; such chains would likely provoke  
21 acidification and compromise cell viability during cell culture. (39) In fact, no  
22 differences were found on the proliferation activity of BM-MSCs between coated  
23 and pure PLLA (Figure 4) and the cells proliferative behavior, by day 14, could  
24 be correlated to other findings on structurally similar PLLA scaffolds. (36)  
25 Interactions between BM-MSCs and their local microenvironment are an  
26 integral part of signaling control of cell attachment, proliferation and  
27 differentiation. So, we investigated the influence of pure and CHT-coated PLLA  
28 scaffolds composition and architecture on the chondrogenic differentiation of  
29 BM-MSCs. A conventional culture system - pellet culture - was used as control,  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 as it provides a 3D environment with high cell density, allowing cell-cell  
4 interactions that mimic mesenchymal cell condensation, an early event of  
5 chondrogenesis during skeletal development. (31, 40)  
6  
7

8  
9  
10 A significant neocartilage formation was observed in pure PLLA, with a cellular  
11 organization analogous to the architecture present in normal articular cartilage  
12 (Figure 5). Interestingly, we found evidence of some differentiated cells, present  
13 in different regions of the scaffolds, which were able to produce zone-specific  
14 molecules, such as lubricin, and thus may be useful in regenerating the upper  
15 layers of articular cartilage. Robust ECM deposition during prolonged culture  
16 was supported by toluidine blue and safranin-O stainings that showed  
17 increasing metachromasia, an indicative of sulfated-GAGs deposition and  
18 accumulation in the matrix (Figure 5). In addition, higher expression of  
19 chondrogenic markers (col-II, aggrecan, Sox9 and Runx1) were obtained when  
20 compared with conventional pellet culture (Figure 6), confirmed on the protein  
21 level (S02). However the expression of hypertrophic markers (col-X, Runx2 and  
22 MMP13) overlapped with the onset of chondrogenesis, corroborated by col-X  
23 expression (Figure 6), and its high positive percentage (Table 2). Furthermore,  
24 the presence of large lacunae is a clear indicative of a switch to a hypertrophic  
25 phenotype (Figure 5, TB). This is not surprising as it known that the induction of  
26 chondrogenic differentiation of MSCs, using TGF- $\beta$ 3 and dexamethasone, can  
27 stimulate terminal differentiation in very early stages, entailing a developmental  
28 program as in embryonic limb development leading to transient cartilage, as  
29 found for the endochondral ossification process. (41, 42)  
30  
31

32 The introduction of chitosan is frequently referred as a positive influence in  
33 accelerating bone or cartilage tissues formation, due to the presence of  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 functional (hydroxyl and amino) groups. (43, 44) From our results, albeit CHT-  
4 coated scaffolds did yield significant cartilage hyaline-like ECM and increased  
5 concomitantly the ratios of col-II/-I and -X (Table 2, PLLA-CHT1, 30d and -  
6  
7  
8  
9  
10 CHT2, 60d), the expression of chondrogenesis-related markers was down-  
11 regulated. Moreover, alizarin red staining was early detected in CHT-coated  
12 scaffolds, colocalized with areas of deposition of a hyaline-like matrix (Figure 5,  
13 Alizarin red, TB and SaO). (45) Yet a higher positivity for this dye could be  
14 triggered by the ability of chitosan to adsorb to anionic dyes, such as seen for  
15 eosin. (24)

16  
17  
18  
19  
20  
21  
22 In particular, hydrogel-like coating in PLLA-CHT1, originated an unevenly cell  
23 distribution and proliferation in two distinct regions. One representing confined  
24 areas of high cellular congregation and matrix production inducing a faster  
25 development of a cartilage-like tissue (Figure 5, TB and SaO) with improved  
26 col-II/-I and -X ratios (Table 2). It is possible that this maturation could be  
27 triggered by local physiologic cues (oxygen tension, pH). (23) Other,  
28 representing areas of poor cell density and a scarcely produced matrix. In  
29 this case, CHT hydrogel-like coating could have slowed cellular infiltration resulting  
30 in decreased cell proliferation, proper cell condensation and/or *in vitro*  
31 chondrogenesis, as seen for other chitosan-coated porous scaffolds. (46, 47)  
32 Altogether, these observations suggest that cells underwent different degrees of  
33 chondrogenesis in different areas of the scaffold depending on the local  
34 composition. Early before, Ma et al., has described hydrogels with spatially  
35 heterogeneous cellular phenotypes and regional variations in ECM proteins,  
36 supporting the formation of heterogeneous structures according to different  
37 matrix components. (48) This could explain the obtained results of transcript  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 levels representing an average of different subpopulations and the spatial  
4  
5 variations in local ECM protein accumulation.

6  
7 In PLLA-CHT2, the cellular organization and morphology were comparable to  
8  
9  
10 pure PLLA. In fact, the fiber-like coating, that remained intact throughout the  
11  
12 experiment, did not practically alter PLLA uniform macroporous structure, as  
13  
14 can be appreciated in SEM micrographs and HE stained sections (Figures 1, A  
15  
16 and C; and 5, dotted red circles in HE). So, in comparison to PLLA-CHT1, it  
17  
18 seems that this fiber-like coating promotes a better chondrogenic response and  
19  
20 at the same time may be hindering the hypertrophic process. This may be  
21  
22 linked to a smaller available surface area that has been suggested to improve  
23  
24 chondrogenesis by increasing the chance for cell-cell interactions as a result of  
25  
26 decreasing the available biomaterial surface per cell. (49) The same authors  
27  
28 compared the effect of chitosan scaffolds structure (macroporous sponges and  
29  
30 microfibers) in the chondrogenesis of MSCs and concluded that it was superior  
31  
32 in the microfibers, which could corroborate our findings. (50)

33  
34 Furthermore, adsorption of adhesive proteins from serum such as fibronectin  
35  
36 has shown to be highly reversible on chitosan, with most of the protein being  
37  
38 desorbed or exchanged in the first 24h which could compromise cell adhesion  
39  
40 and scaffold colonization by cells. (51) Other researchers have described the  
41  
42 low capacity for cell attachment of pure chitosan materials, using chondrocytes.  
43  
44 (34, 37) We found similar results when using BM-MSCs (data not shown).  
45  
46  
47

48  
49  
50 In the future, we believe the induction of the chondrogenic differentiation of BM-  
51  
52 MSCs on CHT-coated PLLA scaffolds can be improved by fine-tuning  
53  
54 fabrication conditions in order to provide guidance for zonal distribution as in  
55  
56 normal articular cartilage. (52) Moreover, further studies are required to  
57  
58  
59  
60

1  
2  
3 elucidate the dependence of the biological response on physicochemical  
4 properties of the scaffolds.  
5  
6

## 7 **5. Conclusion**

8  
9  
10 The incorporation of CHT to PLLA using different methodologies provided either  
11 hydrogel-like (PLLA-CHT1) or fiber-like (PLLA-CHT2) coatings. We found that  
12 the chondrogenic differentiation of BM-MSCs was influenced by the composition  
13 and morphology of pure and CHT-coated PLLA scaffolds. Whilst a hydrogel-like  
14 coating supported the formation of heterogeneous tissues, with confined areas  
15 of matrix maturation or deficient cell condensation, a fiber-like coating induced a  
16 spatial distribution, alike pure PLLA and resembling the articular cartilage zonal  
17 distribution. Nonetheless, chondrogenic differentiation of BM-MSCs in CHT-  
18 coated scaffolds did not result in the production of a stable hyaline cartilage but  
19 rather the development into a transient endochondral cartilage.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29

## 30 **Acknowledgements**

31  
32 The authors are thankful to the microscopy service of UPV for useful help and  
33 service; the Department of Orthopaedic Surgery-CHUAC for providing human  
34 samples; T. H. Gómez and M.J. Sánchez for cell isolation and SCH of INIBIC  
35 for histological processing. The *Biomedical Research Networking Center in*  
36 *Bioengineering, Biomaterials and Nanomedicine* (CIBER-BBN) is a national  
37 initiative of ISCIII. This study was supported by Program ACI-PROMOCIONA  
38 (ACI2010—1095), MAT2010-21611-CO3-01, Iniciativa Ingenio 2010, and  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
Consolider Program.

1  
2  
3  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## References

1. Blanco, F.J., and Ruiz-Romero, C. New targets for disease modifying osteoarthritis drugs: chondrogenesis and Runx1. *Ann Rheum Dis* **72**, 631, 2013.
2. Johnstone, B., Alini, M., Cucchiaroni, M., Dodge, G.R., Eglin, D., Guilak, F., Madry, H., Mata, A., Mauck, R.L., Semino, C.E., and Stoddart, M.J. Tissue engineering for articular cartilage repair--the state of the art. *Eur Cell Mater* **25**, 248, 2013.
3. Hermida-Gómez, T., Fuentes-Boquete, I., Gimeno-Longas, M.J., Muiños-López, E., Díaz-Prado, S., de Toro, F.J., and Blanco, F.J. Bone marrow cells immunomagnetically selected for CD271+ antigen promote in vitro the repair of articular cartilage defects. *Tissue Eng Part A* **17**, 1169, 2011.
4. Alves da Silva, M.L., Martins, A., Costa-Pinto, A.R., Correlo, V.M., Sol, P., Bhattacharya, M., Faria, S., Reis, R.L., and Neves, N.M. Chondrogenic differentiation of human bone marrow mesenchymal stem cells in chitosan-based scaffolds using a flow-perfusion bioreactor. *J Tissue Eng Regen Med* **5**, 722, 2011.
5. Griffon, D.J., Abulencia, J.P., Ragety, G.R., Fredericks, L.P., and Chaieb, S. A comparative study of seeding techniques and three-dimensional matrices for mesenchymal cell attachment. *J Tissue Eng Regen Med* **5**, 169, 2011.
6. Fisher, O.Z., Khademhosseini, A., Langer, R., and Peppas, N.A. Bioinspired materials for controlling stem cell fate. *Acc Chem Res* **43**, 419, 2010.
7. Hu, J., Feng, K., Liu, X., and Ma, P.X. Chondrogenic and osteogenic differentiations of human bone marrow-derived mesenchymal stem cells on a nanofibrous scaffold with designed pore network. *Biomaterials* **30**, 5061, 2009.

- 1  
2  
3 8. Zhang, L., Hu, J., and Athanasiou, K.A. The role of tissue engineering in  
4 articular cartilage repair and regeneration. *Crit Rev Biomed Eng* **37**, 1, 2009.
- 5  
6  
7 9. Magalhães, J., Sousa, R.A., Mano, J.F., Reis, R.L., Blanco, F.J., and San  
8  
9 Román, J. Synthesis and characterization of sensitive hydrogels based on  
10 semi-interpenetrated networks of poly[2-ethyl-(2-pyrrolidone) methacrylate] and  
11 hyaluronic acid. *J Biomed Mater Res A* **101**, 157, 2013.
- 12  
13  
14  
15 10. Ringe, J., and Sittinger, M. Tissue engineering in the rheumatic diseases.  
16  
17  
18 *Arthritis Res Ther* **11**, 211, 2009.
- 19  
20  
21 11. Kretlow, J.D., and Mikos, A.G. 2007 AIChE Alpha Chi Sigma Award: From  
22 Material to Tissue: Biomaterial Development, Scaffold Fabrication, and Tissue  
23 Engineering. *AIChE J* **54**, 3048, 2008.
- 24  
25  
26 12. Nöth, U., Steinert, A.F., and Tuan, R.S. Technology insight: adult  
27  
28  
29 mesenchymal stem cells for osteoarthritis therapy. *Nat Clin Pract Rheumatol* **4**,  
30  
31 371, 2008.
- 32  
33  
34 13. Ni, P., Fu, S., Fan, M., Guo, G., Shi, S., Peng, J., Luo, F., and Qian, Z.  
35 Preparation of poly(ethylene glycol)/polylactide hybrid fibrous scaffolds for bone  
36 tissue engineering. *Int J Nanomedicine* **6**, 3065, 2011.
- 37  
38  
39  
40  
41 14. Deplaine, H., Ribelles, J.L.G., and Ferrer, G.G. Effect of the content of  
42 hydroxyapatite nanoparticles on the properties and bioactivity of poly(L-lactide) –  
43 Hybrid membranes. *Composites Science and Technology* **70**, 1805, 2010.
- 44  
45  
46 15. Wu, S.C., Chang, J.K., Wang, C.K., Wang, G.J., and Ho, M.L.  
47  
48  
49 Enhancement of chondrogenesis of human adipose derived stem cells in a  
50 hyaluronan-enriched microenvironment. *Biomaterials*. England 2010. pp. 631.
- 51  
52  
53 16. Ameer, G.A., Mahmood, T.A., and Langer, R. A biodegradable composite  
54 scaffold for cell transplantation. *J Orthop Res* **20**, 16, 2002.
- 55  
56  
57  
58  
59  
60

- 1  
2  
3 17. Tanaka, T., Hirose, M., Kotobuki, N., Tadokoro, M., Ohgushi, H., Fukuchi,  
4 T., Sato, J., and Seto, K. Bone augmentation by bone marrow mesenchymal  
5 stem cells cultured in three-dimensional biodegradable polymer scaffolds. *J*  
6  
7  
8  
9  
10 Biomed Mater Res A **91**, 428, 2009.
- 11  
12 18. Huang, Q., Goh, J.C., Hutmacher, D.W., and Lee, E.H. In vivo  
13 mesenchymal cell recruitment by a scaffold loaded with transforming growth  
14 factor beta1 and the potential for in situ chondrogenesis. *Tissue Eng* **8**,  
15 469,  
16 2002.  
17  
18
- 19 19. Yang, W., Gomes, R.R., Brown, A.J., Burdett, A.R., Alicknavitch, M.,  
20 Farach-Carson, M.C., and Carson, D.D. Chondrogenic differentiation on  
21 perlecan domain I, collagen II, and bone morphogenetic protein-2-based  
22 matrices. *Tissue Eng* **12**, 2009, 2006.  
23  
24  
25  
26  
27
- 28 20. Di Martino, A., Sittinger, M., and Risbud, M.V. Chitosan: a versatile  
29 biopolymer for orthopaedic tissue-engineering. *Biomaterials* **26**, 5983, 2005.  
30  
31
- 32 21. Zhang, Y., and Zhang, M. Synthesis and characterization of macroporous  
33 chitosan/calcium phosphate composite scaffolds for tissue engineering. *J*  
34  
35  
36  
37  
38  
39  
40
- 41 22. Vaghani, S.S., and Patel, M.M. pH-sensitive hydrogels based on semi-  
42 interpenetrating network (semi-IPN) of chitosan and polyvinyl pyrrolidone for  
43 clarithromycin release. *Drug Dev Ind Pharm* **37**, 1160, 2011.  
44  
45  
46  
47
- 48 23. Vinatier, C., Mrugala, D., Jorgensen, C., Guicheux, J., and Noël, D.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- Cartilage engineering: a crucial combination of cells, biomaterials and  
biofactors. *Trends Biotechnol* **27**, 307, 2009.
24. Silva, J.M., Georgi, N., Costa, R., Sher, P., Reis, R.L., Van Blitterswijk,  
C.A., Karperien, M., and Mano, J.F. Nanostructured 3D Constructs Based on

1  
2  
3 Chitosan and Chondroitin Sulphate Multilayers for Cartilage Tissue Engineering.  
4 PLoS ONE **8**, e55451, 2013.  
5

6  
7 25. Deplaine, H., Lebourg, M., Ripalda, P., Vidaurre, A., Sanz-Ramos, P.,  
8  
9 Mora, G., Prósper, F., Ochoa, I., Doblaré, M., Gómez Ribelles, J.L., Izal-  
10 Azcárate, I., and Gallego Ferrer, G. Biomimetic hydroxyapatite coating on pore  
11 walls improves osteointegration of poly(L-lactic acid) scaffolds. J Biomed Mater  
12 Res B Appl Biomater **101**, 173, 2013.  
13  
14  
15  
16

17  
18 26. Lebourg, M., Suay Antón, J., and Gomez Ribelles, J.L. Hybrid structure in  
19 PCL-HAp scaffold resulting from biomimetic apatite growth. J Mater Sci Mater  
20 Med **21**, 33, 2010.  
21  
22  
23

24  
25 27. He, L., Zhang, Y., Zeng, X., Quan, D., Liao, S., Zeng, Y., Lu, J., and  
26 Ramakrishna, S. Fabrication and characterization of poly(L-lactic acid) 3D  
27 nanofibrous scaffolds with controlled architecture by liquid–liquid phase  
28 separation from a ternary polymer–solvent system. Polymer **50**, 4128, 2009.  
29  
30  
31

32  
33 28. Ho, M.H., Kuo, P.Y., Hsieh, H.J., Hsien, T.Y., Hou, L.T., Lai, J.Y., and  
34 Wang, D.M. Preparation of porous scaffolds by using freeze-extraction and  
35 freeze-gelation methods. Biomaterials **25**, 129, 2004.  
36  
37  
38

39  
40  
41 29. Brandrup, J., and Immergut, E.H. Polymer Handbook. New York: Wiley  
42 Interscience Publication, 1975.  
43

44  
45 30. Cicione, C., Díaz-Prado, S., Muiños-López, E., Hermida-Gómez, T., and  
46 Blanco, F.J. Molecular profile and cellular characterization of human bone  
47 marrow mesenchymal stem cells: donor influence on chondrogenesis.  
48 Differentiation **80**, 155, 2010.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 31. Zhang, L., Su, P., Xu, C., Yang, J., Yu, W., and Huang, D. Chondrogenic  
4 differentiation of human mesenchymal stem cells: a comparison between  
5 micromass and pellet culture systems. *Biotechnol Lett* **32**, 1339, 2010.  
6  
7  
8  
9  
10 32. Livak, K.J., and Schmittgen, T.D. Analysis of relative gene expression data  
11 using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods*  
12 **25**, 402, 2001.  
13  
14 33. Gibson, L.J., and Ashby, M.F. *Cellular Solids: Structure and Properties*.  
15 Cambridge: Cambridge University Press, 1999.  
16  
17 34. Fujihara, Y., Asawa, Y., Takato, T., and Hoshi, K. Tissue reactions to  
18 engineered cartilage based on poly-L-lactic acid scaffolds. *Tissue Eng Part A*  
19 **15**, 1565, 2009.  
20  
21 35. Grad, S., Zhou, L., Gogolewski, S., and Alini, M. Chondrocytes seeded onto  
22 poly (L/DL-lactide) 80%/20% porous scaffolds: a biochemical evaluation. *J*  
23 *Biomed Mater Res A* **66**, 571, 2003.  
24  
25 36. Izal, I., Aranda, P., Sanz-Ramos, P., Ripalda, P., Mora, G., Granero-Moltó,  
26 F., Deplaine, H., Gómez-Ribelles, J.L., Ferrer, G.G., Acosta, V., Ochoa, I.,  
27 García-Aznar, J.M., Andreu, E.J., Monleón-Pradas, M., Doblaré, M., and  
28 Prósper, F. Culture of human bone marrow-derived mesenchymal stem cells on  
29 of poly(L-lactic acid) scaffolds: potential application for the tissue engineering of  
30 cartilage. *Knee Surg Sports Traumatol Arthrosc* **21**, 1737, 2013.  
31  
32 37. Correia, C.R., Moreira-Teixeira, L.S., Moroni, L., Reis, R.L., van Blitterswijk,  
33 C.A., Karperien, M., and Mano, J.F. Chitosan scaffolds containing hyaluronic  
34 acid for cartilage tissue engineering. *Tissue Eng Part C Methods* **17**, 717, 2011.  
35  
36 38. Stolz, M., Raiteri, R., Daniels, A.U., VanLandingham, M.R., Baschong, W.,  
37 and Aebi, U. Dynamic elastic modulus of porcine articular cartilage determined  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 at two different levels of tissue organization by indentation-type atomic force  
4 microscopy. *Biophys J* **86**, 3269, 2004.

5  
6  
7 39. Von Recum, H.A., Cleek, R.L., Eskin, S.G., and Mikos, A.G. Degradation of  
8 polydispersed poly(L-lactic acid) to modulate lactic acid release. *Biomaterials*  
9 **16**, 441, 1995.

10  
11  
12 40. Yang, W., Yang, F., Wang, Y., Both, S.K., and Jansen, J.A. In vivo bone  
13 generation via the endochondral pathway on three-dimensional electrospun  
14 fibers. *Acta Biomater* **9**, 4505, 2013.

15  
16  
17 41. Hellingman, C.A., Koevoet, W., and van Osch, G.J. Can one generate  
18 stable hyaline cartilage from adult mesenchymal stem cells? A developmental  
19 approach. *J Tissue Eng Regen Med* **6**, e1, 2012.

20  
21  
22 42. Goldring, M.B., Tsuchimochi, K., and Ijiri, K. The control of chondrogenesis.  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
J Cell Biochem **97**, 33, 2006.

43. Niu, X., Li, X., Liu, H., Zhou, G., Feng, Q., Cui, F., and Fan, Y.  
Homogeneous chitosan/poly(L-lactide) composite scaffolds prepared by  
emulsion freeze-drying. *J Biomater Sci Polym Ed* **23**, 391, 2012.

44. Jiao, Y., Liu, Z., and Zhou, C. Fabrication and characterization of PLLA-  
chitosan hybrid scaffolds with improved cell compatibility. *J Biomed Mater Res*  
*A* **80**, 820, 2007.

45. Abrahamsson, C.K., Yang, F., Park, H., Brunger, J.M., Valonen, P.K.,  
Langer, R., Welter, J.F., Caplan, A.I., Guilak, F., and Freed, L.E.  
Chondrogenesis and mineralization during in vitro culture of human  
mesenchymal stem cells on three-dimensional woven scaffolds. *Tissue Eng*  
*Part A* **16**, 3709, 2010.

- 1  
2  
3 46. Casper, M.E., Fitzsimmons, J.S., Stone, J.J., Meza, A.O., Huang, Y.,  
4 Ruesink, T.J., O'Driscoll, S.W., and Reinholz, G.G. Tissue engineering of  
5 cartilage using poly-epsilon-caprolactone nanofiber scaffolds seeded in vivo  
6  
7  
8  
9  
10 with periosteal cells. *Osteoarthritis Cartilage* **18**, 981, 2010.  
11  
12 47. Yang, Z., Wu, Y., Li, C., Zhang, T., Zou, Y., Hui, J.H., Ge, Z., and Lee, E.H.  
13 Improved mesenchymal stem cells attachment and in vitro cartilage tissue  
14 formation on chitosan-modified poly(L-lactide-co-epsilon-caprolactone) scaffold.  
15 *Tissue Eng Part A* **18**, 242, 2012.  
16  
17  
18  
19  
20 48. Ma, K., Titan, A.L., Stafford, M., Zheng, C., and Levenston, M.E. Variations  
21 in chondrogenesis of human bone marrow-derived mesenchymal stem cells in  
22 fibrin/alginate blended hydrogels. *Acta Biomater* **8**, 3754, 2012.  
23  
24  
25  
26  
27 49. Ragetty, G.R., Griffon, D.J., Lee, H.B., Fredericks, L.P., Gordon-Evans, W.,  
28 and Chung, Y.S. Effect of chitosan scaffold microstructure on mesenchymal  
29 stem cell chondrogenesis. *Acta Biomater* **6**, 1430, 2010.  
30  
31  
32 50. Ragetty, G.R., Slavik, G.J., Cunningham, B.T., Schaeffer, D.J., and Griffon,  
33 D.J. Cartilage tissue engineering on fibrous chitosan scaffolds produced by a  
34 replica molding technique. *J Biomed Mater Res A* **93**, 46, 2010.  
35  
36  
37  
38  
39 51. Custódio, C.A., Alves, C.M., Reis, R.L., and Mano, J.F. Immobilization of  
40 fibronectin in chitosan substrates improves cell adhesion and proliferation. *J*  
41 *Tissue Eng Regen Med* **4**, 316, 2010.  
42  
43  
44  
45  
46 52. Klein, T.J., Malda, J., Sah, R.L., and Hutmacher, D.W. Tissue engineering  
47 of articular cartilage with biomimetic zones. *Tissue Eng Part B Rev* **15**, 143,  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Reprint author: Francisco J. Blanco. Servicio de Reumatología. Instituto de  
4 Investigación Biomédica de A Coruña (INIBIC). Complejo Hospitalario  
5 Universitario de A Coruña (CHUAC). Sergas. Universidade da Coruña (UDC).  
6  
7

8  
9  
10 As Xubias, 15006. A Coruña, Spain.  
11

## 12 13 14 **Figures and Tables**

15  
16 Fig. 1. SEM micrographs of cross-sections of PLLA (A); CHT (B); PLLA-CHT1  
17 (D), where CHT forms smooth pellicles, indicated by an arrow, over PLLA  
18 macroporous structure; and PLLA-CHT2 (D), where CHT forms a fibrous-like  
19 coating over PLLA micropores. Scale bars represent 500  $\mu\text{m}$ .  
20

21  
22 Fig. 2. TGA thermogram of unmodified and modified PLLA (a) and the water  
23 absorption ratios (b) of PLLA, CHT, PLLA-CHT1 and -CHT2 scaffolds.  
24  
25

26  
27 Fig. 3. Stress strain curves for PLLA, CHT, PLLA-CHT1 and -CHT2, in the dry  
28 (a) and wet (b) state. Variations on the (c) elastic modulus ( $E'$ ) and (d) yield  
29 strength ( $Y_s$ ) for PLLA, CHT, PLLA-CHT1 and -CHT2 scaffolds ( $n = 5$ ).  
30 Experiments are reported for dry ( ) and wet ( ) samples.  
31

32  
33 Fig. 4. BM-MSCs viability during 30 days in PLLA, PLLA-CHT1 and -CHT2  
34 scaffolds. Significant differences were found in different time points ( $*p < 0.05$ )  
35 although no difference was observed among the different scaffolds nor TCPS.  
36

37  
38 Fig. 5. Histological (HE, TB, Sa-O, Von Kossa and alizarin red) and  
39 immunolocalization (col-I, -II and -X, aggrecan and lubricin) analysis in cross-  
40 sections of PLLA, PLLA-CHT1 and -CHT2 scaffolds seeded with BM-MSCs,  
41 after 30 and 60 days, in a chondrogenic differentiation medium.  
42  
43

44  
45 Fig. 6. Fold-change in mRNA levels of chondrogenesis and hypertrophy in BM-  
46 MSCs cultured in PLLA, PLLA-CHT1 and -CHT2 scaffolds, normalized against  
47  
48  
49

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

expression levels of conventional pellet culture (dashed lines), after 30 and 60 days. Data represents the mean  $\pm$  SD (n = 2-3). Symbols (\*; † and ‡) indicate statistically significant differences ( $p < 0.05$ ) in the expression levels at different time points and among the different scaffolds.

Table 1. List of primers used for qRT-PCR.

Table 2. Collagens (I, II and X) positivity and ratios (col-II/-I and -X) in cell-constructs, after 30 and 60 days, in chondrogenic medium. The results are represented in positive percentage regarding the total area of matrix produced.




Fig. 1. SEM micrographs of cross-sections of PLLA (A); CHT (B); PLLA-CHT1 (D), where CHT forms smooth pellicles, indicated by an arrow, over PLLA macroporous structure; and PLLA-CHT2 (D), where CHT forms a fibrous-like coating over PLLA micropores. Scale bars represent 500  $\mu\text{m}$ .  
147x53mm (150 x 150 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Fig. 2. TGA thermogram of unmodified and modified PLLA (a) and the water absorption ratios (b) of PLLA, CHT, PLLA-CHT1 and -CHT2 scaffolds.  
215x90mm (150 x 150 DPI)




Fig. 3. Stress strain curves for PLLA, CHT, PLLA-CHT1 and -CHT2, in the dry (a) and wet (b) state. Variations on the (c) elastic modulus ( $E'$ ) and (d) yield strength ( $Y_s$ ) for PLLA, CHT, PLLA-CHT1 and -CHT2 scaffolds ( $n = 5$ ). Experiments are reported for dry (■) and wet (□) samples.

212x143mm (150 x 150 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Fig. 4. BM-MSCs viability during 30 days in PLLA, PLLA-CHT1 and -CHT2 scaffolds. Significant differences were found in different time points (\* $p < 0.05$ ) although no difference was observed among the different scaffolds nor TCPS.  
137x103mm (150 x 150 DPI)






Fig. 5. Histological (HE, TB, Sa-O, Von Kossa and alizarin red) and immunolocalization (col-I, -II and -X, aggrecan and lubricin) analysis in cross-sections of PLLA, PLLA-CHT1 and -CHT2 scaffolds seeded with BM-MSCs, after 30 and 60 days, in a chondrogenic differentiation medium  
100x137mm (150 x 150 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Fig. 6. Fold-change in mRNA levels of chondrogenesis and hypertrophy in BM-MSCs cultured in PLLA, PLLA-CHT1 and -CHT2 scaffolds, normalized against expression levels of conventional pellet culture (dashed lines), after 30 and 60 days. Data represents the mean  $\pm$  SD (n = 2-3). Symbols (\*; † and ‡) indicate statistically significant differences (p < 0.05) in the expression levels at different time points and among the different scaffolds.

226x161mm (150 x 150 DPI)

Table 1. List of primers used for qRT-PCR.

Gene	Forward	Reverse	Probes	Gene Bank A. Number
<b>B2M</b>	TTCTGGCCTGGAGGCTATC	TCAGGAAATTTGACTTTCCATTC	42	NM_004048.2
<b>RPL13a</b>	CAAGCGGATGAACACCAAC	TGTGGGGCAGCATACTC	28	NM_012423.2
<b>Sox9</b>	GTACCCGCACTTGCACAAC	TCGCTCTCGTTCAGAAGTCTC	61	NM_000346
<b>Aggrecan</b>	CGGTCTACCTCTACCCTAACCA	GAGAAGGAACCGCTGAAATG	38	NM_013227.3
<b>Col-I</b>	CTGGCCCCATTGGTAATGT	ACCAGGGAAACCAGTAGCAC	1	NM_000088.3
<b>Col-II</b>	TGGTGCTAATGGCGAGAAG	CCCAGTCTCTCCACGTTTAC	4	NM_001844.4
<b>Col-X</b>	CACCTTCTGCACTGCTCATC	GGCAGCATATTCTCAGATGGA	6	NM_000493.3
<b>Runx1</b>	ACAAACCCACCGCAAGTC	CATCTAGTTTCTGCCGATGTCTT	21	NM_001122607.1
<b>Runx2</b>	CACCATGTCAGCAAACTTCTT	TCACGTCGCTCATTTTGC	41	NM_001024630.3
<b>MMP13</b>	CCAGTCTCCGAGGAGAAACA	AAAAACAGCTCCGCATCAAC	73	NM_002427.3
<b>OPN</b>	CGCAGACCTGACATCCAGT	GGCTGTCCCAATCAGAAGG	61	NM_000582.2

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Table 2. Collagens (I, II and X) positivity and ratios (col-II/-I and -X) in cell-constructs, after 30 and 60 days, in chondrogenic medium. The results are represented in positive percentage regarding the total area of matrix produced.

	col-I (%)	col-II (%)	col-X (%)	col-II/-I ratio	col-II/-X ratio
<b>30 days</b>					
PLLA	18.59	37.26	41.97	2	0.88
PLLA-CHT1	18.92	35.33	28.93	1.80	1.22
PLLA-CHT2	11.85	13.44	13.38	1.13	1.00
<b>60 days</b>					
PLLA	66.72	19.50	69.11	0.29	0.28
PLLA-CHT1	72.20	6.48	61.08	0.09	0.11
PLLA-CHT2	28.88	14.46	15.76	0.50	0.91


Table S01. Molecular weight of PLLA in the different samples

Sample	Mn (kDa)	Mw	Polidispersity Index
PLLA	65.6	117564	1.79
PLLA-CHT1	64.3	123233	1.91
PLLA-CHT2	61.1	121187	1.98

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

e

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



Supplementary Figure  
89x133mm (150 x 150 DPI)

Distribution

## Supplementary Materials and Methods

### Molecular weight determination

Molecular weight distribution of PLLA scaffolds pure or CHT-coated was studied by gel permeation chromatography (GPC) using a chromatograph (Waters 1525) fitted with a Binary HPLC pump (Waters 2414 Refractive Index Detector) and four serial columns (Styragel), using tetrahydrofurane (THF) as the mobile phase. Flow rate was 1.0 mL/min and the samples were prepared with 1% (w/v) in THF/Dioxane (50/50 v/v) as solvent. The concept of universal calibration was used to estimate the molecular weight of pure PLLA, using monodisperse polystyrene standards SM-105 (Showa Denko) according to the procedure reported by Painter et al. using  $K_{\text{PLLA}} = 5.45 \times 10^5 \text{ dL/g}$  and  $\alpha_{\text{PLLA}} = 0.73$ , and the Mark-Houwink-Sakurada parameters for PLLA.

### References

- Liu, L., Fishman, M.L., Hicks, K.B., and Liu, C.K. *J Agric Food Chem* **53**, 9017, 2005.
- Painter, P.C., and Coleman, M.M. *Fundamentals of Polymer Science: An Introductory Text*. Lancaster: Technomic Pub Co, 1997.